Private Advisor Group’s TherapeuticsMD TXMD Stock Holding History

Private Advisor Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-40	Closed	-$3K	–	3297
2020 Q2	$3K	Buy	+40	New	+$2.33K	﹤0.01%	3481

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Private Advisor Group's TXMD Position: Q3 2020 in Review

Private Advisor Group sold out of TherapeuticsMD (TXMD) in Q3 2020, closing a stake of 40 shares — an estimated $3K sold.

Private Advisor Group first reported a position in TXMD in Q2 2020 and held it in 1 quarter. The position peaked at $3K in Q2 2020. 142 funds tracked by Wall St. Rank hold TXMD as of Q3 2020.

Private Advisor Group reported no remaining TherapeuticsMD position as of Q3 2020 after selling out during the quarter.
Private Advisor Group sold 40 TherapeuticsMD shares in Q3 2020, an estimated $3K.
Private Advisor Group first reported a position in TherapeuticsMD in Q2 2020 and held it in 1 quarter.
Private Advisor Group's TherapeuticsMD position peaked at $3K in Q2 2020.
142 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.